Edwards Lifesciences (EW)
NYSE: EW · Medical Devices · Irvine, CA
Our rating: Neutral
Neutral reaffirmed at $100.82, moderate conviction, November 5, 2026.
Breaks if: The neutral call moves cautious if revenue growth decelerates below 8% year-over-year in two consecutive quarterly reports — at that pace, 55x earnings becomes indefensible regardless of franchise quality. It moves positive if revenue growth reaccelerates to 14% or above for two consecutive quarters and operating margins expand, suggesting the premium multiple is earnable. Neither condition is true at today's reported figures.
Key figures
| Market value | $58.6B |
|---|---|
| Revenue, last 12 months | $6.7B |
| Net income, last 12 months | $1.0B |
| Free cash flow, last 12 months | $1.4B |
| Price to earnings | 57.3× |
| Free cash flow yield | 2.4% |
| Dividend yield | 0.0% |
| Operating margin | 21.6% |
| Return on equity | 9.7% |
| Beta to the S&P 500 | 0.55 |
| Volatility, annualized | 31.9% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $1.7B | 10.5% | $0.53 | $507M |
| June 30, 2026 | $1.7B | 13.6% | $0.42 | $585M |
| March 31, 2026 | $1.6B | 16.7% | $0.66 | −$21M |
| December 31, 2025 | $1.6B | 13.3% | $0.16 | $354M |
| September 30, 2025 | $1.6B | 14.7% | $0.50 | $516M |
| June 30, 2025 | $1.5B | 11.9% | $0.56 | $241M |
| March 31, 2025 | $1.4B | 6.2% | $0.61 | $224M |
| December 31, 2024 | $1.4B | 9.4% | $0.65 | −$177M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $1.78B: Claude 42%, Gemini 80%, Mistral 62%
- Diluted earnings per share are at least $0.16: Claude 91%, Gemini 95%, Mistral 94%
- Free cash flow for the quarter is at least $0.35B: Claude 58%, Gemini 65%, Mistral 85%
11 ledger entries and 16 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.